Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SPDR Series Trust - SPDR S&P Biotech ETF XBI

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).


ARCA:XBI - Post by User

SPDR Series Trust - SPDR S&P Biotech ETF
<< Previous
 Bullboard Posts
User Avatar Image
(135)
•••
  • inviolablspiritX
Post by inviolablspiriton Apr 08, 2025 10:32am
16 Views
Post# 36528882

CEO Nick Kadysh - Pharmala Biotech Interview

CEO Nick Kadysh - Pharmala Biotech InterviewFor investors interested in the psychedelics sector of biotech.  Pharmala Biotech the #1 supplier of GMP MDMA for clinical trials worldwide.  The company is a supplier of MDMA for commercial purposes and for clincial trials and research and they research and develop their own novel MDMA molecules.

#AlphaNooner - Nick Kadysh PharmAla Biotech
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities